Home

Briggs Morrison

CIK 1654430 · President, Head of R&D · last filed 2026-06-26

Briggs Morrison is a President, Head of R&D who has filed 64 SEC Form 4 insider transactions across 8 companies since 2017. The most recent filing, for ARVN, was dated Jun 26, 2026. Across all open-market trades the lifetime net is −$27.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.6M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.58M

Companies

8

Total Filings

64

Lifetime Open-Market Net

-$27.68M

Filer Profile

Reported Address
C/O SYNDAX PHARMACEUTICALS, INC.
400 TOTTEN POND ROAD, SUITE 110
WALTHAM, MA 02451
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARVN Director 111,548 $8.45 $942.6K -$2.18M 14 2026-06-26
CRSP Director — $51.72 — $0 2 2026-06-09
HOWL Director — $0.98 — $0 5 2025-06-13
Carisma Therapeutics Inc. (CARM) Delisted Director — $0.00 — $0 2 2024-06-27
Repare Therapeutics Inc. (RPTX) Delisted Director 4,800 $2.65 $12.7K $96.0K 5 2024-06-20
SNDX Director 34,836 $18.18 $633.3K -$25.70M 27 2024-02-09
Codiak BioSciences, Inc. (CDAK) Delisted Director 4,761 $0.06 $271 $100.0K 2 2021-02-17
NXTC Director — $7.00 — $0 2 2020-06-15

Recent Filings

64 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-26 ARVN Grant (A) +15,527 $0 EDGAR
2026-06-09 CRSP Grant (A) — $0 EDGAR
2026-03-09 ARVN Buy (P) +20,000 $268.1K EDGAR
2025-09-24 ARVN Buy (P) +30,000 $227.0K EDGAR
2025-06-27 ARVN Grant (A) +16,025 $0 EDGAR
2025-06-13 HOWL Grant (A) — $0 EDGAR
2025-06-06 CRSP Grant (A) — $0 EDGAR
2024-06-27 Carisma Therapeutics Inc. (CARM) Delisted Grant (A) — $0 EDGAR
2024-06-20 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) — $0 EDGAR
2024-05-31 ARVN Grant (A) +5,899 $0 EDGAR
Showing 1–10 of 64
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.